🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔥 New in JACC Journals #JACCHF Excellent Review on 🎯 Current landscape of Tx for ATTR-CM 1. Review of Current Tx : 2 stabilizers, one Silencer 2. What should be first choice for Tx? Switch? Add on? 3. Despite increased awareness, many remain undiagnosed

Hospitals Acquired By Private Equity Firms: Increased Postoperative Mortality For Common Inpatient Surgeries Adrian Diaz Justin B. Dimick Health Affairs UMich CHOP healthaffairs.org/doi/abs/10.137…

Open it. Zoom it. Save it. Share it. This is your go-to guide for standard adult TTE views.

Incredibly proud of our team for our donor utilization initiative. jacc.org/doi/10.1016/j.… Happy to share templates, report add and dashboard code. 🙏🏽vanguard speakers Ajmera Transplant Centre UHN The ISHLT JACC Journals Ted Rogers Centre for Heart Research Kiran Khush Candice Silversides Maryjane Farr MD MSc, FACC FAST FHFSA FAHA

In-depth analysis of the effects of #exvivo machine perfusion on outcomes following DBD heart transplantation reveals that machine perfusion is associated with enhanced 90-day post-transplant survival in recipients with preservation times ≥4 hours or donor age ≥45 years. These

26 years ago today…

Diastolic Perfusion Pressure Predicts Response to Inotropes and Vasopressors and Benefit From Mechanical Circulatory Support in Cardiogenic Shock #AHAJournals ahajrnls.org/4mlQrtx

📣🔥Read our ‘Practical Guide on Induction Immunosuppression in 🫀 #Transplant led by the brilliant #AndrianaNikolava 🏷️Limited data in standard-risk #HT pts 🏷️Induction safe in LVAD, efficacy unclear 🏷️rATG > IL2RA for high-risk 🎯Need for prospective, mechanistic studies

In this issue, Smalcova et al share how an #ECPR program boosted organ donation after cardiac arrest—donors rose from 7 to 42, and organs donated from 18 to 119—all with good 5-year outcomes. A powerful case for ECPR’s broader impact. #organdonation 🔗: jhltonline.org/article/S1053-…

Left Atrial Reverse Remodeling in Patients Supported with Durable Left Ventricular Assist Devices and Clinical Implications Josef Stehlik Thomas Hanff, MD MSCE Joseph Taleb Christos P. Kyriakopoulos Stavros George Drakos University of Utah Health U of U Cardiovascular Medicine University of Utah Department of Internal Medicine UofU Nora Eccles Harrison CVRTI #AHAJournals ahajrnls.org/4koqXKf

Stanford Heart Failure, Cardiac Transplant and MCS's Erik Henricksen & Kiran Khush tackle the ❓of upper limit of age for 🫀transplant from an SRTR analysis. ➡️Stanford Medicine summary: shorturl.at/jVmUf ➡️JHLT: pubmed.ncbi.nlm.nih.gov/39122221/ Eldrin Lewis Sunny Varshney, MD Ronald Witteles Alex Sandhu euan ashley Stanford University

Burnout doesn’t ask for permission—it creeps in quietly, even when you’re doing what you love. Medicine is a calling, but it’s also a marathon. If you’re tired, you’re not weak—you’re human. Rest is not a reward. It’s a requirement. Take care of the healer too. 🧠💛 #Burnout

📣 The 2024 Annual Report from the #ISHLT International Thoracic Organ Transplant Registry is now available online to members. This official relaunch of the Registry includes new data from 12 global partners covering 🫀+🫁 transplantations from 1992 to 2024. Read the report: 🔗

Transplant Tuesday tidbit: #GrandMarshal @pearlsoflife.org

Do you think you fully understand hemodynamics? Guess again. This MUST-READ paper illustrates the numerous parameters that should be evaluated when resuscitating a patient in shock. 🎩 tip to the authors. What a fantastic team of great people on this one. eddyjoemd.com/foamed

Recipients of #DCD hearts with extended ex-vivo heart perfusion duration may have worse survival outcomes. Transplant teams should exercise caution in considering hearts with extended perfusion times. #DCDTransplant Ruby Singh Asishana Osho, MD, MPH 🔗: jhltonline.org/article/S1053-…

♻️ 💔Recovered EF ≠ recovered risk Finerenone delivers—LVEF history doesn’t change that 🔹 HFimpEF = 5% of trial pop, median EF rise: +12% 🔸 CV event rates still high (21.4 vs 16.0 per 100 pt-yrs) 🔹 Finerenone benefit consistent: RR 0.72 in HFimpEF 🔸 Greater absolute risk

Carvedilol as Single Therapy for Heart Failure With Improved Ejection Fraction: A CATHEDRAL-HF Withdrawal of HF treatment maintaining carvedilol vs usual treatment led to similar rates of worsening of left ventricular function at 52 weeks jacc.org/doi/abs/10.101…

💥 #ATTR-CM treatment isn’t one-size-fits-all anymore. #JACC’s latest review breaks down how #FDA-approved therapies and next-gen agents are reshaping the field. jacc.org/doi/10.1016/j.… #Amyloidosis #HELIOSB #Tafamidis #Vutrisiran #Acoramidis Kushal Kadakia Harlan Krumholz Michelle Kittleson MD PhD

Practical Guide on the Use of Induction Immunosuppression in Heart Transplantation Anju Bhardwaj MD FACC Nadia Fida Priya Umapathi Luise Holzhauser, MD #AHAJournals ahajrnls.org/43bJzYr